SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Torrent Pharmaceuticals Ltd (TORNTPHARM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500420 NSE: TORNTPHARM Pharmaceuticals & Drugs | Large Cap | Torrent Pharma Share Price

₹4,418.70 81.05 (1.87%)

As on 05-Jun'26 16:59

Torrent Pharmaceuticals Ltd (TORNTPHARM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500420 NSE: TORNTPHARM Pharmaceuticals & Drugs | Large Cap | Torrent Pharma Share Price

₹4,418.70 81.05 (1.87%)

As on 05-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹1,46,806 Cr.
Current Price
₹4,418.7
52-Week Low / High
₹3,134 / 4,715
TTM EPS
₹63.9
TTM Sales
₹13,980 Cr.
Book Value per Share
₹247.9
P/E Ratio
67.86
Higher than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
17.50
Higher than its 5-year historical median
Price to Sales (P/S)
10.50
Higher than its 5-year historical median
EV/EBITDA
35.93
Higher than its 5-year historical median
Dividend Yield
0.90%
Profitability Efficiency
Return on Equity (ROE)
26.76%
Outperforms industry median
Return on Capital Employed (ROCE)
19.27%
In line with industry median
Return on Assets (ROA)
7.37%
Operating Profit Margin
32.6%
Net Profit Margin
15.29%
Gross Profit Margin
20.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
21.39%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
18.05%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
11.87%
Asset Quality
Promoter Holding
68.31%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹8,219 Cr.
Equity
₹169.2 Cr.
Face Value
₹5
All Time Low / High
₹4.06 / 4714.50

Torrent Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Very Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Torrent Pharmaceuticals Ltd a good quality company?
Torrent Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Torrent Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Torrent Pharmaceuticals Ltd vs industry peers?
Torrent Pharmaceuticals Ltd revenue CAGR is 7.72%, compared to the industry median CAGR of 9.92%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Torrent Pharmaceuticals Ltd?
Promoters hold 68.31% of the Torrent Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Torrent Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21.1% based on the current price.
View More

DeciZen - make an informed investing decision on Torrent Pharma

Decision Maker
Consolidated basis

1. Right Stock

10 Year X-ray Pro
Long Term Prospect

2. Right Price

Right Price
Price Chart

3. Right Time ⓘ

Right Price
#Likely Future 5 Year CAGR.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Torrent Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ20.4%13.8%9.8%15.3%17.6%14.4%20.3%24.3%27.3%19.3%-
Value Creation
Index ⓘ		0.80.2-0.10.40.60.30.81.21.40.7-

Growth Parameters ⓘ
Sales ⓘ5,8165,9507,6737,9398,0058,5089,62010,72811,51613,98013,980
Sales YoY Gr.-2.3%29%3.5%0.8%6.3%13.1%11.5%7.4%21.4%-
Adj EPS ⓘ23.11419.5283628.336.346.856.968.663.9
YoY Gr.--39.1%38.8%43.5%28.8%-21.3%28.2%28.9%21.6%20.4%-
BVPS (₹) ⓘ128.5136.6139.6142.5172.5175.9183.1202.6224.3247.8247.9
Adj Net
Profit ⓘ		7814756599461,2199591,2291,5851,9272,3202,163
Cash Flow from Ops. ⓘ1,0098941,7981,3932,0051,8032,3683,2662,5853,023-
Debt/CF from Ops. ⓘ2.57.23.44.22.42.22.21.21.24.9-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ10.2%11.8%13.3%21.4%
Adj EPS ⓘ12.9%13.7%23.6%20.4%
BVPSⓘ7.6%7.5%10.6%10.5%
Share Price 20.5% 25.8% 35.2% 40.1%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		19.910.614.119.822.916.320.224.326.72925.8
Op. Profit
Mgn % ⓘ		23.722.525.827.33128.629.531.432.332.633.2
Net Profit
Mgn % ⓘ		13.488.611.915.211.312.814.816.716.415.5
Debt to
Equity ⓘ		0.61.41.31.20.80.70.90.60.41.81.4
Working Cap
Days ⓘ		21612310510811711610710711112094
Cash Conv.
Cycle ⓘ		-6-58-56-46-32-15-1-411618

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales5,8165,9507,6737,9398,0058,5089,62010,72811,51613,980
Operating Expenses ⓘ + 4,4384,6095,6965,7695,5246,0776,7967,3647,8129,607
Manufacturing Costs610576691672674735726716732905
Material Costs1,6301,5352,0411,9821,9602,2312,5132,4592,5563,124
Employee Cost 9931,1351,4041,4291,4401,5261,6781,9842,2032,671
Other Costs ⓘ 1,2051,3621,5601,6861,4511,5841,8792,2052,3212,907
Operating Profit ⓘ 1,3771,3411,9762,1702,4802,4312,8243,3643,7044,373
Operating Profit Margin (%) 23.7%22.5%25.8%27.3%31.0%28.6%29.4%31.4%32.2%31.3%
Other Income ⓘ + 223307641215719763624092
Exceptional Items ⓘ 00-35700-485088-24-89
Interest ⓘ 206308504451353255333354252385
Depreciation ⓘ 3074096186546586627078087951,119
Profit Before Tax ⓘ 1,0889315621,1871,5261,2261,8472,3522,6732,872
Tax ⓘ 155253125162274449602696762734
Profit After Tax 9346784361,0251,2527771,2451,6561,9112,138
PAT Margin (%) 16.1%11.4%5.7%12.9%15.6%9.1%12.9%15.4%16.6%15.3%
Adjusted EPS (₹)27.620.012.930.337.023.036.848.956.563.9
Dividend Payout Ratio (%)25.40%34.90%66%52.90%47.30%104.50%59.80%57.20%56.70%59.50%

Valuation of Torrent Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 4,3504,6224,7244,8235,8375,9536,1986,8567,5918,388
Share Capital ⓘ 858585858585169169169169
Reserves ⓘ 4,2664,5384,6404,7395,7535,8686,0296,6877,4218,219
Debt +2,2415,7374,8474,3953,6453,0464,2613,2412,44214,566
Long Term Debt2,2414,1113,9133,3042,9412,1232,4961,6041,19211,651
Short Term Debt01,6269341,0917049231,7651,6381,2502,915
Minority Interest0100000009196
Trade Payables1,7492,0482,0972,0492,0671,6741,6792,0891,8202,358
Others Liabilities ⓘ 1,0511,5592,0832,3102,1041,9332,3302,3182,5439,106
Total Liabilities ⓘ 9,39213,96713,75113,57713,65312,60614,46814,50514,39643,614

Fixed Assets

Net Fixed Assets ⓘ +3,6887,8557,7487,5337,0656,4238,1218,1387,94733,178
Gross Block4,9109,4499,93510,33410,51210,72812,81213,48514,04140,405
Accumulated Depreciation1,2211,5952,1882,8013,4474,3064,6905,3466,0947,227
CWIP ⓘ 519647617712889630765361478641
Investments ⓘ 8044923532181226199173156948
Inventories1,5591,9661,9352,1482,6812,4622,2302,2792,5413,138
Trade Receivables9511,2531,4361,6491,5231,6321,9441,8441,8663,031
Cash Equivalents 8948678166676044035718395791,165
Others Assets ⓘ 9778868468657108296388728281,512
Total Assets ⓘ 9,39213,96713,75113,57713,65312,60614,46814,50514,39643,614

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 1,0098941,7981,3932,0051,8032,3683,2662,5853,023
PBT ⓘ 1,0889315621,1871,5261,2261,8472,3522,6732,872
Adjustment ⓘ 4306071,4188769931,3509379949961,301
Changes in Working Capital ⓘ -125-36099-386-338-352-18418-481-342
Tax Paid ⓘ -384-284-281-284-176-421-398-498-603-809
Cash Flow From Investing Activity ⓘ + -787-4,707-241199-449-197-2,415-168-540-12,712
Capex -486-789-661-403-334-196-415-299-594-636
Net Investments -17538395585-121-8-1311834203
Others ⓘ -126-3,956241757-1,9871320-12,279
Cash Flow From Financing Activity ⓘ + -1933,417-1,314-1,549-1,651-1,78177-2,780-2,29810,151
Net Proceeds from Shares ⓘ 0000000000
Net Proceeds from Borrowing ⓘ 2052,339238-451-543-1,033423-1,236-52910,318
Interest Paid ⓘ -191-276-503-485-356-258-303-371-262-427
Dividend Paid ⓘ -204-265-310-719-338-677-863-1,015-1,083-1,289
Others ⓘ -31,619-740106-413187820-157-4241,549
Net Cash Flow ⓘ 29-39524242-95-17530319-253461

Financial Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)23.815.129.3421.4723.4913.1820.525.3826.4626.76
ROCE (%)20.3613.819.7515.2817.6214.3520.3224.2827.3219.27
Asset Turnover Ratio0.640.961.051.091.091.161.211.151.170.68
PAT to CFO Conversion(x)1.081.324.121.361.62.321.91.971.351.41
Working Capital Days
Receivable Days74.7035.7033.8037.7038.9037.904041.4040.2045.40
Inventory Days90.9057.204949.8059.2061.7052.5049.3052.2052.70
Payable Days449451.50370.60381.80383.20306.10243.50279.70279.20244.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Torrent Pharmaceuticals Ltd FAQs

The current trading price of Torrent Pharma on 05-Jun-2026 16:59 is ₹4,418.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Torrent Pharma stood at ₹1,46,805.8 Cr

The latest P/E ratio of Torrent Pharma as of 04-Jun-2026 is 66.99.

The latest P/B ratio of Torrent Pharma as of 04-Jun-2026 is 17.37.

The 52-week high of Torrent Pharma is ₹4,714.5 and the 52-week low is ₹3,134.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Torrent Pharma is ₹10,712 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Torrent Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Torrent Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Torrent Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals, the flagship company of the Torrent Group, is one of the leading Pharma companies in India. The company is pioneers in initiating the concept of niche marketing in India and are ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI), women healthcare (WHC), Vitamins Minerals & Nutrients (VMN) and Cosmo-Dermatology. 

The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma has crossed many geographical boundaries. Through strategic expansions, the company consistently strengthened its global footprint, establishing a robust manufacturing base in India and extending its commercial presence across the world. Its state-of-the-art manufacturing facilities and R&D centre, combined with an expanding global network, enable it to bring high-quality medicines to diverse markets. 

Business area of the company

The Company is engaged in manufacturing, developing and marketing of generic pharmaceutical formulations. Torrent Pharma is a leading player in the areas of Cardiovascular and Central Nervous Systems, having achieved significant presence in segments of Nephrology, Oncology, Pulmonology, Gynecology and Pediatric treatments. 

Business segments

The company operates in two key business segments - Branded Generics (BGx) and Generics (Gx). Each segment plays a pivotal role in its growth strategy, catering to diverse therapeutic needs across different regions.

Branded Generics (BGx): Focuses on manufacturing, marketing and distributing affordable alternatives to off-patented drugs under its own brand names.

Generics (Gx): Specialises in manufacturing generic pharmaceutical products after patent exclusivity expires, focusing on markets with regulatory approval for generics.

Therapeutic Areas of the company

  • Anti-Diabetic
  • Anti-Microbial
  • Cardiovascular
  • Dermatologic
  • Urology
  • Pain
  • Gastro Intestinal
  • Gynecology
  • Miscellaneous
  • Oncology
  • Nephrology
  • Neuro-Psychiatric

Awards and recognition

  • 1984-85 Received Chemexcil Export Award
  • 1984-85 Received Udyog Ratna Award
  • 1985-86 Received Chemexcil Export Award
  • 1986-87 Received Chemexcil Export Award
  • 1986-87 Received IDMA Quality Excellence Award
  • 1986-87 Received Export Award from Govt. of Gujarat
  • 1987-88 Received Export Award from Govt. of Gujarat
  • 1989-90 Received Chemexcil Trishul Award for highest Pharma Exports
  • 1989-90 Received IDMA Quality Excellence Award
  • 1988-89 Received Chemexcil Export Award
  • 1990-91 Received Export Award from Govt. of Gujarat
  • 1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship
  • 1991-92 Received Export Award from Govt. of Gujarat
  • 1991-92 Received National Export Award
  • 1992-93 Received IDMA Quality Excellence Award
  • 1999-00 GCCI Export Appreciation Award
  • 1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.
  • 2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
  • 2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility
  • 2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2009-10 Baddi Plant awarded Five Star rating by British Safety Council
  • 2012-13 Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category

Accreditation

Approvals research centre

  • National GLP Compliance Monitoring Authority, India*
  • National Accreditation Board for Testing & Calibration Laboratories (NABL), India*
  • ISO 14001:2004 and OHSAS 18001:2007, ISOQAR Ltd., UK*
  • ISO 50001 : 2011, ISOQAR Ltd. UK*

(*Also applicable for Bio-Evaluation Center)

Bio-evaluation centre accreditations

  • The Drug Controller General (India) (DCGI)
  • ANVISA (BRAZIL)
  • Ministry of Health (UAE)

Studies inspected and approved

  • USFDA
  • AFFSAPS (ANSM)
  • DKMA
  • AGES
  • ANVISA

Studies accepted by Regulatory Agencies in:

  • Russia
  • CIS Countries
  • Australia
  • ASEAN countries
  • South Africa
  • African countries
  • South American countries

Milestones

  • 1959: U. N. Mehta started Pharma operations.
  • 1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.
  • 1980: First manufacturing facility set up at Vatva in Ahmedabad
  • 1983: Entry into the international markets. First Export order to USSR received
  • 1984: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1984: Torrent Laboratories Limited received Udyog Ratna Award.
  • 1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.
  • 1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.
  • 1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1985: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1987: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1989: Second manufacturing plant commissioned at Indrad
  • 1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.
  • 1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1988: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1990: Torrent Exports Limited received National Export Award.
  • 1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.
  • 1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1995: Torrent Gujarat Biotech Limited plant commissioned.
  • 1996: U N Mehta bestowed with the title of Corporate Business Man of the Year
  • 1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.
  • 1998: State-of-the-art R&D Centre commissioned.
  • 1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.
  • 1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.
  • 1999: First New Chemical Entity Patented by Torrent Research Center
  • 1999: GCCI Export Appreciation Award
  • 1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.
  • 2000: Indrad Plant received ISO 9001:2000 Certificate
  • 2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).
  • 2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation
  • 2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility
  • 2001: Torrent do Brasil Ltda. set up in Brazil
  • 2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.
  • 2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:1999
  • 2002: Torrent's R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002:
  • 2002: Board for Testing and Calibration Laboratories (NABL).
  • 2002: Addition of a new marketing division, MIND
  • 2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)
  • 2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2002: Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
  • 2003: Torrent Pharma Inc. set up in USA.
  • 2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant
  • 2003: Torrent Pharma Philippines Inc. set up.
  • 2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals
  • 2004: Restructuring of marketing divisions and addition of new division, Delta.
  • 2004: Torrent Australasia Pty Ltd. incorporated in Australia
  • 2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.
  • 2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.
  • 2005: Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany.
  • 2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.
  • 2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
  • 2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL
  • 2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval
  • 2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products
  • 2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body
  • 2007: Construction of Sikkim Plant started
  • 2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany
  • 2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
  • 2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market
  • 2009: Baddi Plant awarded Five Star rating by British Safety Council
  • 2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda
  • 2010: An advanced facility for Stability Studies set up at Indrad Plant
  • 2010: Entered into the therapeutic area of Gynaecology
  • 2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico
  • 2010: Started construction of Dahej manufacturing facility
  • 2010: Commissioned a subsidiary in United Kingdom and Romania
  • 2010: Torrent Research Center develops Long Acting Injectables technology
  • 2010: Foray into oncology segment
  • 2011: Sikkim Plant commences operation
  • 2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center
  • 2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment
  • 2012: Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2012: Topical Foams system developed by Torrent Research Center
  • 2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
  • 2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal
  • 2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment
  • 2014: Torrent Pharma's Dahej Plant commences operations
  • 2015: Torrent acquires 100% stake of Zyg Pharma
  • 2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2016: Dahej Plant receives USFDA approval
  • 2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited
  • 2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.
  • 2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
  • 2017: Acquired Women Healthcare brands from Novartis
  • 2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
  • 2019: Torrent & Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India
  • 2021: Torrent Pharmaceuticals enters into voluntary licensing agreement with Lilly for Baricitinib for Covid-19 in India
  • 2021: Cipla, Dr. Reddy’s, Emcure, Sun Pharma and Torrent to collaborate for clinical trial of Molnupiravir for COVID-19
  • 2022: Torrent Pharma enters into agreement with Dr Reddy's Laboratories
  • 2023: Torrent Pharmaceuticals forays into OTC segment with calcium supplement brand
  • 2023: Torrent Pharmaceuticals enters into licensing and supply agreement with Zydus Lifesciences
  • 2024: Torrent Pharmaceuticals incorporates Wholly Owned Subsidiary in Colombia
  • 2024: Torrent Pharmaceuticals enters into patent licensing agreement with Takeda
  • 2024: Torrent Pharma enters into agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
  • 2025: Torrent Pharmaceuticals raises Rs 200 crore through Commercial Papers
  • 2025: Torrent Pharmaceuticals raises Rs 300 crore through Commercial Papers 
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×